TIER - ETF AI Analysis
Top Page
T. Rowe Price International Equity Research ETF (TIER)
TIER, the T. Rowe Price International Equity Research ETF, earns a solid overall rating driven largely by high-quality holdings like TSM and ASML, which benefit from strong financial performance, positive earnings sentiment, and strategic positioning in advanced technologies and AI. Additional support comes from well-established names such as AstraZeneca, HSBC, and Novartis, all showing strong fundamentals and constructive outlooks, though some holdings face valuation concerns and signs of overbought or short-term bearish momentum. The main risk factor is the fund’s meaningful exposure to a handful of large, globally focused companies where high valuations and technical caution could lead to periods of volatility.
TIER vs. SPDR S&P 500 ETF (SPY)
- AUM
- 137.11M
- Region
- Global Ex-U.S.
- Expense Ratio
- 0.38%
- Beta
- 1.01
- Issuer
- T. Rowe Price
- Inception Date
- Jun 25, 2025
- Dividend Yield
- 0.68%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
TIER Summary
T. Rowe Price International Equity Research ETF (TIER) is an actively managed fund that invests in a wide range of companies outside the U.S., following a broad international “total market” theme rather than tracking a specific index. It holds well-known global names like TSMC, Samsung Electronics, ASML, AstraZeneca, and HSBC, across many sectors and regions, including Europe and Asia. Investors might consider TIER for global diversification and long-term growth potential guided by T. Rowe Price’s research team. A key risk is that international stock prices can rise or fall sharply with global markets and currency swings.
How much will it cost me?
The T. Rowe Price International Equity Research ETF (Ticker: TIER) has an expense ratio of 0.38%, which means you’ll pay $3.80 per year for every $1,000 invested. This is slightly higher than the average for passively managed ETFs because it is actively managed, leveraging T. Rowe Price's in-depth research to select stocks globally.
What would affect this ETF?
The TIER ETF, with its focus on global equities outside the U.S., could benefit from economic growth in emerging markets and technological advancements, particularly given its exposure to companies like Tencent, TSMC, and Samsung. However, it may face challenges from geopolitical tensions, regulatory changes in key regions like China, and global economic slowdowns, which could impact sectors such as financials and technology. Additionally, currency fluctuations and rising interest rates could affect international investments and overall performance.
TIER Top 10 Holdings
TIER is leaning heavily on the global chip boom, with TSMC, SK hynix, Samsung, and ASML acting as the fund’s main growth engine as semiconductor names keep climbing, even if ASML has cooled a bit lately. Financial heavyweights like HSBC and Royal Bank of Canada are providing a steadier tailwind, helping smooth out volatility. On the flip side, big pharma players such as AstraZeneca and Novartis have been losing steam, modestly dragging on returns. Overall, it’s a diversified ex-U.S. mix, but with a clear tilt toward tech-driven growth overseas.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 TSM | TSMC | 2.43% | $3.33M | $1.88T | 33.94% | 81Outperform |
 KR:000660 | SK hynix Inc. | 1.74% | $2.39M | KRW 1033.53T | 149.65% | ―― |
 GB:SMSN | Samsung Electronics | 1.30% | $1.79M | $1.07T | 127.79% | ―― |
 ASML | ASML Holding | 1.90% | $2.60M | $602.71B | 45.60% | 81Outperform |
 AU:BHP | BHP Group Ltd | 0.88% | $1.20M | AUD 292.61B | 31.18% | 68Neutral |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 GB:HSBA | HSBC Holdings | 0.80% | $1.10M | GBP 218.81B | 19.37% | 80Outperform |
 RY | Royal Bank Of Canada | ― | ― | ― | ― | 75Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 CH:NOVN | Novartis AG | 0.88% | $1.21M | CHF 244.89B | 35.30% | 80Outperform |
TIER Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TIER, the sentiment is Negative. The current price of 31.00 is below the 20-day moving average (MA) of 31.55, below the 50-day MA of 32.24, and below the 200-day MA of 31.26, indicating a bearish trend. The MACD of -0.28 indicates Negative momentum. The RSI at 37.74 is Neutral, neither overbought nor oversold. The STOCH value of 71.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TIER.
TIER Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| TIER | $31.01 | $35.00(12.89% Upside) | $137.11M | 0.38% | 63Neutral |
 JDVI | $38.93 | $45.81(17.69% Upside) | $817.11M | 0.69% | 60Neutral |
 BRIE | $29.47 | $35.80(21.47% Upside) | $704.11M | 0.34% | 59Neutral |
 OSEA | $29.81 | $37.09(24.41% Upside) | $370.76M | 0.55% | 71Outperform |
 QLTI | $27.76 | $32.80(18.13% Upside) | $283.55M | 0.60% | 61Neutral |
 BAIV | $28.79 | $31.90(10.78% Upside) | $191.35M | 0.60% | 60Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TIER | T. Rowe Price International Equity Research ETF | 31.00 | 3.48 | 12.64% | |
| JDVI | John Hancock Disciplined Value International Select ETF | 38.93 | 5.43 | 16.20% | |
| BRIE | MFS Blended Research International Equity ETF | 29.47 | 4.29 | 17.06% | |
| OSEA | Harbor International Compounders ETF | 29.81 | -0.36 | -1.19% | |
| QLTI | GMO International Quality ETF | 27.76 | 1.94 | 7.53% | |
| BAIV | Brown Advisory International Value Select ETF | 28.79 | 3.21 | 12.53% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.